Navigation Links
Novartis Makes Accessing Prescription Assistance and Disease Management Programs Simpler and Easier for Patients
Date:7/30/2008

One-stop Web site and toll-free number provide patients with important

information to better manage their health

EAST HANOVER, N.J., July 30 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced the launch of Patient Assistance Now -- a new, comprehensive resource that integrates both Novartis and non-Novartis programs that may help uninsured Americans afford their Novartis medicines and find information to take care of their health. Now patients can access an easy-to-use Web site that provides specific information about programs and services available. Patients and caregivers can visit http://www.PatientAssistanceNow.com or call toll-free 1-800-245-5356 to find programs that may be right for them.

Novartis is offering solutions for improved access to affordable medicines for the more than 47 million Americans who have no prescription drug coverage(1). While many assistance programs and resources are available to benefit the uninsured, patients are often unable to find these programs, or are confused when determining which programs best fit their individual needs.

"We at Novartis are proud to offer Patient Assistance Now to make it easier for patients to find options that help them access important programs to learn more about their health conditions and available treatments. For years, Novartis patient assistance programs have been providing free medicines to millions of uninsured patients," said Kevin Rigby, Vice President of Public Affairs at Novartis Pharmaceuticals Corporation. "By integrating our programs and resources, Novartis continues to seek to have a meaningful impact on patients' lives."

Patient Assistance Now provides patients with access to all of the information and tools offered by Novartis to assist patients with managing their health, including:

-- Novartis Access to Medicines Programs, some of which provide fr
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case
2. Novartis, Pfizer and Merck Take the Lead on Strong Relationships with Physicians, as Doctors Demand an Expanding Set of Services
3. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
4. Novartis and Sony Pictures Television Internationals Latin American Advertising Sales Group Launch Partnership to Create Multi-Media Platform for Breast Cancer Awareness, Detection, and Treatment in Latin America
5. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
6. Novartis Vaccines to Host Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
7. Novartis Vaccines Partners With RediClinic for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
8. Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers
9. Novartis Vaccines Launches National Gift-Giving Program to Help Protect Loved Ones by Reserving an Influenza Vaccination
10. Dr. Web Makes Many Americans Question Trusted Health Providers
11. BCBSNC Makes Electronic Prescribing Available Statewide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)..., study suggests , , THURSDAY, Jan. 8 (...rongly they would react to racist acts, a new Cana...y participants at York University, in Toronto, sti... person rather than a black one, even after their ...rson when he left the room. , "And the racist...
(Date:1/8/2009).../ -- Allscripts-Misys Healthcare,Solutions, Inc.,...llscripts or,the Company), today announced its fi...d November 30, 2008. , (Logo: http://www.n...) , The Company,s results for the three and...ts from legacy Allscripts for the period of Octobe...
(Date:1/8/2009)...wire/ -- A new educational Web site offers expert ...ical products and medical devices from the Agency ...Education and Research on Therapeutics (CERTs), a ...eading research centers nationwide. The Clinician...AIN ) http://www.chainonline.org links clinician...
(Date:1/8/2009)...Call/ -- Heska Corporation (Nasdaq: HSKA ) annou... Heska Corporation Invites You to Join Its Fourth... Conference Call on the Web, When: Monda... www.heska.com (click on the Q4 and Year-End 200...age of this website)., How: Live over t...
Breaking Medicine News(10 mins):Health News:Many Turn Blind Eye to Racism 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 2Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 3Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 4Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 5Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 6Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 7Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 8Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 9Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 10Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 11Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 12Health News:Allscripts Reports Fiscal 2009 Second Quarter Results 13Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Webcast Alert: Heska Announces Fourth Quarter and Year-End 2008 Earnings Conference Call Webcast 2
...esearchers say eating fish could help keep ones mi... high intake of cholesterol and saturated fat have...middle age. More and more research is showing what... for dementia. For example, studies have shown tha...
... risk factor, which accounts for about half of the...e is now a more dependable, less expensive test to... the NMP22 tumor marker assay in 1,331 patients at...s found that of the 79 patients shown to have blad...
...ound in the air in many inner-city homes could be ...n children say researchers. According to researche...ously exposed to the allergy-causing substance fou... the air and exposure increases their risk for dev...
...sted early onset wheezing is associated with high ...d bronchial hyper-responsiveness. Children with th... more severe asthma. However, some children who de...ith the same characteristics as those who begin wh...
Other Medicine News:
(Date:1/7/2009)... ImQuest Life Sciences announced today the success...nd Drug Administration to initiate human clinical ...r IQP-0410. ImQuest anticipates initiating their P...410 is a novel small molecule inhibitor of HIV whi...criptase inhibitor (NNRTI). The compound possesses...
(Date:1/6/2009)...from prior U.S., U.K. and China Trials , , SAN .... (VTI), a development stage company targeting liv... begun for a randomized, controlled, multi-center,...orporeal Liver Assist Device (ELAD) as a treatment... three protocols. The study is open for enrollment...
(Date:1/6/2009)...ewswire/ -- Sequella, Inc., a clinical-stage bioph...ic potential, announced today that SQ109, its lead...(TB), was the first drug approved for evaluation i...port Vaccine Company LLC and Quintiles Transnation...e of Allergy and Infectious Diseases (NIAID), Nati...
(Date:1/5/2009)...ne Pharmaceuticals announced today that it has ini...otein kinase inhibitor, CX-4945, in patients with ...tiple myeloma. The primary endpoints of the oral d...tolerance and PK properties of CX-4945 and to sele...dition, multiple mechanism-related pharmacodynamic...
Breaking Medicine Technology:ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 2ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 1PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard 28TM 29 in The U S 3500 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 1China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 2China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 3China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 4China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 5China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 6China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 7China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 8China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 9China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 10China Nepstar Chain Drugstore Reports Third Quarter 2008 Results 30671 11Sentillion Appoints New UK Sales Manager 30669 1Sentillion Appoints New UK Sales Manager 30669 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 1Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 2Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 3Lt Col Weinstein New Book 3A Universal Health Care Will Not Work Unless 30664 4
...gress of European Hematology,Association (EHA) -, ...ll/ --,Immunomedics, Inc. , a biopharmaceutical co...to treat cancer and other serious,diseases, today ...,of EHA in Vienna, Austria, showed positive respon...treated with a new,radioimmunotherapy (RAIT) using...
...--Jun 11, 2007 - Geron,Corporation (Nasdaq:GERN) t...s indicating that GRNOPC1, the company,s human,emb...treatment of,spinal cord injury, evades a direct a...ron scientist Ross Okamura at the Federation of,Cl...the findings,could mean that patients treated with...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 2Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: